4D Molecular Therapeutics, Inc. (FDMT): Total Assets
$566.71M
As of 2025-12-31
$492.62M
As of 2026-06-30
+29.4%
3-year compound annual growth
+14.5%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $566.71M | +1.1% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $560.38M | +64.9% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $339.89M | +29.8% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $261.85M | -25.9% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $353.49M | +22.6% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $288.33M | +395.1% | 2022-03-28, Balance as of period end |
| 2019-12-31 | $58.23M | n/a | 2021-03-25, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $566.71M | +1.1% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $244.43M | -9.4% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $589.07M | -24.7% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.47B | +1.8% |
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $173.83M | -55.1% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $143.01M | +16.6% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $223.70M | -36.7% |
Compare FDMT, MGTX, AUTL, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗